Study guide
Toxoplasmosis and herpetic necrotizing retinitis
European Board of Ophthalmology Diploma EBOD
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: EBOD Examination, Applications and Regulations
EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals
2 Chapter 2: Physical Optics, Photometry and Lenses
Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid
3 Chapter 3: Instrument Optics, Aberrations and Laser Physics
Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT
4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing
Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses
5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation
Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics
6 Chapter 6: Extraocular Anatomy and Motor Physiology
Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys
7 Chapter 7: Binocular Vision and Amblyopia
Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment
8 Chapter 8: Childhood Assessment and Strabismus Testing
Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts
9 Chapter 9: Esotropia, Exotropia and Vertical Deviations
Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew
10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery
Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles
11 Chapter 11: ROP and Paediatric Ocular Disease
Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding
12 Chapter 12: Ocular Surface Anatomy and Infection
Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis
13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation
Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis
14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies
Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies
15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure
Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency
16 Chapter 16: Surface Reconstruction and Keratoplasty
Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems
17 Chapter 17: Lens Development, Cataract Assessment and Biometry
Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry
18 Chapter 18: IOL Planning and Phacoemulsification
Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques
19 Chapter 19: Cataract Anaesthesia and Surgical Complications
Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO
20 Chapter 20: Corneal and Intraocular Refractive Surgery
Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange
21 Chapter 21: Presbyopia Procedures and Surface Therapeutics
Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin
22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy
Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation
23 Chapter 23: Angle, Disc and Visual-Field Assessment
Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry
24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms
Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure
25 Chapter 25: POAG, Angle Closure and Pigmentary Disease
POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma
26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment
Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers
27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion
Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions
28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy
Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis
29 Chapter 29: Inherited Retina and Electrophysiology
Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina
30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid
AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum
31 Chapter 31: Retinal Breaks and Detachment Repair
PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling
32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma
Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment
33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation
SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation
34 Chapter 34: Infectious Uveitis and Endophthalmitis
Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment
35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy
Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison
36 Chapter 36: Papilloedema, IIH and Afferent Localisation
Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization
37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology
Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies
38 Chapter 38: Central Motor Control and Cranial Nerve Palsies
Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus
39 Chapter 39: Myasthenia and Ocular Myopathy
Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome
40 Chapter 40: Pupillary Pathways and Anisocoria
Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials
41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment
Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation
42 Chapter 42: Lid Repair and Lacrimal Drainage
Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR
43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours
Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma
44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease
Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling
45 Chapter 45: Ocular Trauma and Vascular Systemic Disease
Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease
46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology
Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects
47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations
Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal
Toxoplasmosis and herpetic necrotizing retinitis
Key Takeaways Explain This Topic AI
Toxoplasma treatment follows lesion threat and immune status; steroids require appropriate antimicrobial coverage.
ARN requires prompt antiviral treatment, supportive sampling and close monitoring for detachment.
Laser or early vitrectomy is individualized rather than a compulsory preventive procedure for every necrotizing-retinitis case.
Last updated: October 2026
Ocular Toxoplasmosis
Ocular toxoplasmosis is caused by Toxoplasma gondii , an obligate intracellular apicomplexan protozoan parasite. It represents the single most frequent cause of infectious posterior uveitis worldwide, accounting for 30% to 50% of posterior uveitis cases in Europe.
Life Cycle and Transmission
Definitive Hosts: Members of the cat family ( Felidae ), in which the sexual reproduction cycle occurs, shedding unsporulated oocysts in faeces.
Intermediate Hosts: Humans, livestock, rodents, and birds, in which asexual replication occurs.
Routes of Human Infection:
- Ingestion of tissue cysts in raw or undercooked meat (pork, lamb, beef);
- Ingestion of sporulated oocysts via contaminated water, unwashed soil-grown vegetables, or cat litter;
Transplacental vertical transmission of tachyzoites during primary acute maternal infection during pregnancy.
Historical vs. Modern Understanding: Historically believed to be almost entirely due to late reactivation of congenital infection, current epidemiological evidence confirms that a significant proportion of adult cases represent newly acquired, postnatal infections.
Clinical Presentation
The Classic Lesion: A solitary, focal, elevated, fluffy yellowish-white patch of active necrotising retinochoroiditis with feathery, poorly demarcated borders. The primary infection resides within the neurosensory retina, with secondary granulomatous involvement of the underlying choroid.
The "Satellite Lesion": In over 70% of reactivation cases, the active inflammatory focus arises immediately adjacent to the pigmented, atrophic margin of an old, healed chorioretinal scar.
"Headlamp in the Fog": Intense focal inflammatory vitritis situated directly over the active retinochoroidal lesion creates the characteristic ophthalmoscopic appearance of a bright yellow headlight shining through dense fog.
Associated Features:
Kyrieleis Arteriolitis: Segmental, glistening, bead-like, yellowish-white intra-arteriolar accumulations along retinal arterioles near or distant from the lesion. This represents an inflammatory endothelial response/immune-complex vasculitis rather than direct parasitic infiltration of the vessel wall, and resolves without leaving vascular occlusions.
Jensen Disease (Papillitis / Neuroretinitis): An active toxoplasmic lesion situated adjacent to or directly on the optic nerve head, producing profound visual loss, an afferent pupillary defect, marked disc swelling, and a secondary macular fan/star.
Anterior Spill-over: Granulomatous or non-granulomatous anterior uveitis accompanied by high intraocular pressure secondary to trabeculitis.
Evidence-Based Treatment Regimens for Ocular Toxoplasmosis
Not every toxoplasmosis lesion requires antimicrobial intervention. In immunocompetent hosts, small, peripheral lesions far from the macula and optic disc resolve spontaneously over 6 to 8 weeks. However, systemic antimicrobial therapy is strictly indicated for: lesions within 1 to 2 disc diameters of the fovea or optic disc, lesions threatening major retinal vascular arcades, large lesions ( > 2 – 3 disc diameters >2\text{--}3\text{ disc diameters} > 2 – 3 disc diameters ), severe vitritis ( > 2 + >2+ > 2 + haze), or any lesion in an immunocompromised or monocular patient.
Classic Triple / Quadruple Therapy:
Pyrimethamine: 100 mg 100\text{ mg} 100 mg oral loading dose on day 1 (divided as two 50 mg 50\text{ mg} 50 mg doses), followed by 25 – 50 mg once daily 25\text{--}50\text{ mg once daily} 25 – 50 mg once daily orally for 4 to 6 weeks.
Sulfadiazine: 2.0 g 2.0\text{ g} 2.0 g oral loading dose, followed by 1.0 g 1.0\text{ g} 1.0 g orally four times daily ( 4 g/day 4\text{ g/day} 4 g/day ) for 4 to 6 weeks.
Folinic Acid (Leucovorin): 10 – 25 mg 10\text{--}25\text{ mg} 10 – 25 mg orally three times weekly (co-administered to prevent pyrimethamine-induced dihydrofolate reductase inhibition, bone marrow suppression, and megaloblastic anaemia; folic acid must not be substituted ).
Oral Prednisolone: 0.5 – 1.0 mg/kg/day 0.5\text{--}1.0\text{ mg/kg/day} 0.5 – 1.0 mg/kg/day , introduced 24 to 48 hours AFTER starting antimicrobial coverage, and tapered off before discontinuing antiparasitic agents.
Alternative Standard Regimen (Co-Trimoxazole):
Trimethoprim/Sulfamethoxazole (Co-Trimoxazole 800 / 160 mg 800/160\text{ mg} 800/160 mg ): One double-strength tablet orally twice daily for 4 to 6 weeks, combined with adjunctive oral prednisolone. Co-trimoxazole is an alternative used in appropriate patients; regimen selection depends on allergy, pregnancy, immune status, lesion threat and monitoring requirements.
Local Intravitreal Therapy:
Intravitreal Clindamycin ( 1.0 mg 1.0\text{ mg} 1.0 mg ) combined with Dexamethasone ( 400 μ g 400\,\mu\text{g} 400 μ g ) in 0.1 mL 0.1\text{ mL} 0.1 mL . Excellent option for pregnant patients (avoiding systemic teratogenicity), patients with severe sulfa allergy, or those non-compliant with oral therapy.
Caution
THE STEROID SAFETY MANDATE IN TOXOPLASMOSIS: Systemic corticosteroids must NEVER be administered as monotherapy or without concurrent antimicrobial coverage in ocular toxoplasmosis. Steroid monotherapy eliminates host cell-mediated immune control, permitting unrestrained tachyzoite proliferation that leads to fulminant, massive retinal necrosis, panophthalmitis, and permanent blindness.
Herpetic Necrotising Retinopathies
Herpetic viral necrotising retinitis comprises two devastating clinical syndromes caused by members of the Herpesviridae family.
1. Acute Retinal Necrosis (ARN)
ARN occurs predominantly in immunocompetent individuals of either sex and any age, though it can also affect immunosuppressed hosts:
Etiology: Varicella Zoster Virus (VZV) is the causative agent in the majority of cases ( 65 % ~65\% 65% , typically in patients aged > 50 years >50\text{ years} > 50 years ), followed by Herpes Simplex Virus type 1 (HSV-1) in older adults, and Herpes Simplex Virus type 2 (HSV-2) in young individuals ( < 25 years <25\text{ years} < 25 years ). Cytomegalovirus (CMV) is a rare cause.
American Uveitis Society (AUS) Diagnostic Criteria: The diagnosis of ARN is entirely clinical and defined by four cardinal features:
One or more discrete foci of full-thickness retinal necrosis with sharp, scalloped borders situated in the peripheral retina outside the major vascular arcades;
Rapid, circumferential, progressive expansion of necrosis along the peripheral retina if untreated;
Occlusive retinal vasculopathy with prominent arteriolar involvement (severe peri-arteritis, luminal thrombosis, and non-perfusion);
Prominent intraocular inflammation: dense vitritis and granulomatous/non-granulomatous anterior uveitis.
Bilateral Involvement: Without systemic antiviral therapy, contralateral eye involvement (Bilateral Acute Retinal Necrosis / BARN) develops in up to 30% to 50% of patients , typically within 2 to 12 weeks (and up to several years later).
Complications: Rhegmatogenous Retinal Detachment (RRD) develops in 50% to 75% of eyes , typically occurring 4 to 12 weeks after the initial infection. Detachment results from vitreous traction acting upon paper-thin, atrophic necrotic retina, creating multiple, large, irregular, circumferential retinal breaks along the boundary between necrotic and healthy retina.
Management Protocol:
Induction Antiviral: Intravenous Aciclovir ( 10 mg/kg 10\text{ mg/kg} 10 mg/kg IV every 8 hours for 7 to 14 days) OR high-dose Oral Valaciclovir ( 1.0 – 2.0 g 1.0\text{--}2.0\text{ g} 1.0 – 2.0 g orally three times daily) .
Intravitreal Antiviral: Immediate co-administration of Intravitreal Foscarnet ( 2.4 mg in 0.1 mL 2.4\text{ mg in }0.1\text{ mL} 2.4 mg in 0.1 mL ) or Ganciclovir ( 2.0 mg in 0.1 mL 2.0\text{ mg in }0.1\text{ mL} 2.0 mg in 0.1 mL ) at presentation provides rapid local therapeutic drug levels while awaiting systemic saturation.
Maintenance Antiviral: Long-term oral valaciclovir ( 1.0 g 1.0\text{ g} 1.0 g three times daily for 6 weeks, then 1.0 g 1.0\text{ g} 1.0 g daily for 3 to 12 months) to protect the fellow eye from BARN.
Systemic Corticosteroids: Oral prednisolone ( 0.5 – 1.0 mg/kg/day 0.5\text{--}1.0\text{ mg/kg/day} 0.5 – 1.0 mg/kg/day ) introduced 24 to 48 hours AFTER starting antiviral coverage to clear vitritis and reduce tractional bands.
Selected prevention: Discuss laser or early vitrectomy individually; routine 360-degree laser for all ARN is not established.
2. Progressive Outer Retinal Necrosis (PORN)
PORN is a variant of herpetic retinitis occurring almost exclusively in severely immunocompromised individuals , classically patients with advanced HIV/AIDS exhibiting CD4 + < 50 cells/ μ L \text{CD4}^+ < 50\text{ cells/}\mu\text{L} CD4 + < 50 cells/ μ L :
Etiology: Reactivation of Varicella Zoster Virus (VZV) .
characteristic Hallmarks:
Deep, multifocal, yellowish-white outer retinal opacification (involving the deep sensory retina and RPE);
Striking absence of intraocular inflammation: minimal or absent vitritis and anterior chamber reaction ("quiet eye") because the host lacks sufficient CD4+ T-lymphocytes to mount an inflammatory response;
- Early and prominent involvement of the posterior pole and fovea;
- Rapid coalescence of lesions producing a "cracked mud" fundus appearance;
Fulminant, relentlessly destructive course leading to total retinal detachment and no light perception within days to weeks. Requires aggressive dual IV antivirals (ganciclovir + foscarnet) combined with repeated intravitreal injections and immediate systemic antiretroviral therapy (ART).